A Phase 3 interventional study of Follitropin Delta (FE 999049) and Follitropin Alfa (GONAL-F) in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 13 sites in 11 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 2nd registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2014.
This study's enrollment of 513 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 18th registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial investigates the immunogenicity of FE 999049 in repeated cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Follitropin Delta (FE 999049) (COS cycle 2)
Drug: Follitropin Delta (FE 999049)
Follitropin Alfa (GONAL-F) (COS cycle 2)
Drug: Follitropin Alfa (GONAL-F)
Follitropin Delta (FE 999049) (COS cycle 3)
Drug: Follitropin Delta (FE 999049)
Follitropin Alfa (GONAL-F) (COS cycle 3)
Drug: Follitropin Alfa (GONAL-F)
Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles
The proportion (percentage) of participants with at least one treatment-induced anti-FSH antibody response at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.
Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles
The proportion (percentage) of participants with treatment-induced anti-FSH antibodies with neutralising capacity at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.
Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity, After One and After Two Repeated Controlled Ovarian Stimulation Cycles
The proportion (percentage) of participants with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated COS cycles is presented.
Time frame: Stimulation day 1, 7-10 days after last FE 999049 or GONAL-F dose and 21-28 days after last FE 999049 or GONAL-F dose
Proportion (Percentage) of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS for Each Controlled Ovarian Stimulation Cycle
The proportion (percentage) of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
Time frame: ≤9 days after triggering of final follicular maturation.
Proportion (Percentage) of Subject With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response for Each Controlled Ovarian Stimulation Cycle
Proportion (percentage) of participants with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.
Time frame: 5-6 weeks after blastocyst transfer
Implantation Rate for Each Controlled Ovarian Stimulation Cycle
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.
Time frame: 5-6 weeks after blastocyst transfer
Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle
Ongoing pregnancy rate was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.
Time frame: 10-11 weeks after blastocyst transfer
Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle
Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.
Time frame: 10-11 weeks after blastocyst transfer
Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle
Participants self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessment performed is presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
Proportion (Percentage) of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade) for Each Controlled Ovarian Stimulation Cycle
Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.
Time frame: >9 days after triggering of final follicular maturation
Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle
Incidences of confirmed technical malfunction of administration pen are presented.
Time frame: End-of-stimulation (up to 20 stimulation days)
A total of 32 investigational sites included participants to the trial : 3 in Belgium, 3 in Brazil, 3 in Canada, 3 in the Czech Republic, 2 in Denmark, 2 in Italy, 2 in Poland, 2 in Russia, 10 in Spain and 2 in United Kingdom.
| Milestone | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Started | 252 | 261 | 0 | 0 |
| Completed | 238 | 254 | 0 | 0 |
| Not completed | 14 | 7 | 0 | 0 |
| Withdrew: Protocol violation | 8 | 3 | 0 | 0 |
| Withdrew: Adverse event | 3 | 4 | 0 | 0 |
| Withdrew: Personal reasons | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Started | 0 | 0 | 95 | 93 |
| Completed | 0 | 0 | 89 | 91 |
| Not completed | 0 | 0 | 6 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 |
| Withdrew: Personal reasons | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
The proportion (percentage) of participants with at least one treatment-induced anti-FSH antibody response at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) |
|---|---|---|
| Proportion (Percentage) of Subjects With Treatment-induced Anti-Follicle-Stimulating Hormone (FSH) Antibodies After up to Two Repeated Controlled Ovarian Stimulation Cycles | 0.79 (0.10 to 2.84) | 0.38 (0.01 to 2.12) |
The proportion (percentage) of participants with treatment-induced anti-FSH antibodies with neutralising capacity at any time point is presented. The cumulative incidences in COS cycle 2 and COS cycle 3 divided by participants in COS cycle 2 are presented. Participants with observations in both cycles are only counted once.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) |
|---|---|---|
| Proportion (Percentage) of Subjects With Treatment-induced Anti-FSH Antibodies With Neutralising Capacity After up to Two Repeated Controlled Ovarian Stimulation Cycles | 0.00 (0.00 to 1.45) | 0.00 (0.00 to 1.40) |
The proportion (percentage) of participants with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated COS cycles is presented.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Treatment-induced anti-FSH antibodies | 0.79 (0.10 to 2.84) | 0.38 (0.01 to 2.12) | 1.05 (0.03 to 5.73) | 1.08 (0.03 to 5.85) |
| Antibodies with neutralising capacity | 0.00 (0.00 to 1.45) | 0.00 (0.00 to 1.40) | 0.00 (0.00 to 3.81) | 0.00 (0.00 to 3.89) |
The proportion (percentage) of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Early OHSS (any grade) | 0.8 | 2.3 | 1.1 | 0.0 |
| Early OHSS (moderate/severe) | 0.0 | 1.9 | 0.0 | 0.0 |
| Any preventive intervention | 1.6 | 1.9 | 0.0 | 1.1 |
| Early OHSS (any grade) / preventive | 2.0 | 3.8 | 1.1 | 1.1 |
| Early OHSS (moderate/severe) / preventive | 1.6 | 3.8 | 0.0 | 1.1 |
Proportion (percentage) of participants with cycle cancellation due to poor ovarian response, excessive ovarian response, and triggering with gonadotropin-releasing hormone (GnRH) agonist are presented.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Cycle cancelled due to poor ovarian response | 2.0 | 3.8 | 2.1 | 2.2 |
| Cycle cancelled due to excessive ovarian response | 0.4 | 0.0 | 0.0 | 0.0 |
| Triggering with GnRH agonist | 0.4 | 0.8 | 0.0 | 1.1 |
Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after blastocyst transfer.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Vital Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle | 29.4 (23.8 to 35.4) | 27.2 (21.9 to 33.0) | 27.4 (18.7 to 37.5) | 29.0 (20.1 to 39.4) |
Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of blastocysts transferred.
| Percentage | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Implantation Rate for Each Controlled Ovarian Stimulation Cycle | 34.6 (28.8 to 40.8) | 30.6 (25.2 to 36.5) | 28.8 (21.2 to 37.3) | 32.2 (24.0 to 41.3) |
Ongoing pregnancy rate was defined as at least one intrauterine viable fetus 10-11 weeks after blastocyst transfer.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Ongoing Pregnancy Rate for Each Controlled Ovarian Stimulation Cycle | 27.8 (22.3 to 33.7) | 25.7 (20.5 to 31.4) | 27.4 (18.7 to 37.5) | 28 (19.1 to 38.2) |
Ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by number of blastocysts transferred.
| Percentage | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Ongoing Implantation Rate for Each Controlled Ovarian Stimulation Cycle | 28.7 (23.3 to 34.7) | 25.5 (20.4 to 31.1) | 25.0 (17.9 to 33.3) | 28.9 (21.0 to 37.9) |
Participants self-assessed injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after each injection. The injection site reactions were assessed as none, mild, moderate and severe. The frequency of injection site reactions (mild, moderate or severe) based on all assessment performed is presented.
| Percentage of events | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Frequency of Injection Site Reactions (Redness, Pain, Itching, Swelling and Bruising) Assessed by the Subject During the Stimulation Period for Each Controlled Ovarian Stimulation Cycle | 3.0 | 2.4 | 2.8 | 2.3 |
Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Late OHSS (any grade) | 0.4 | 0.8 | 1.1 | 1.1 |
| Late OHSS (moderate/severe) | 0.0 | 0.8 | 0.0 | 1.1 |
Incidences of confirmed technical malfunction of administration pen are presented.
| Percentage of participants | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Technical Malfunctions of the Administration Pen for Each Controlled Ovarian Stimulation Cycle | 0.0 | 0.0 | 0.0 | 0.0 |
Collected over Adverse events (AEs) were recorded from signed informed consent to the end-of-cycle visit for COS cycle 2 (up to approximately 4.5 months) and again from screening to the end-of-cycle visit for COS cycle 3 (up to approximately 4.5 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 (COS Cycle 2) | 0/252 (0%) | 4/252 (1.6%) | 70/252 (27.8%) |
| GONAL-F (COS Cycle 2) | 0/261 (0%) | 4/261 (1.5%) | 77/261 (29.5%) |
| FE 999049 (COS Cycle 3) | 0/95 (0%) | 0/95 (0%) | 26/95 (27.4%) |
| GONAL-F (COS Cycle 3) | 0/93 (0%) | 1/93 (1.1%) | 34/93 (36.6%) |
| Event | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| Ovarian hyperstimulation syndromeReproductive system and breast disorders | 0/252 | 1/261 | 0/95 | 1/93 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/252 | 2/261 | 0/95 | 0/93 |
| Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions | 1/252 | 1/261 | 0/95 | 0/93 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/252 | 0/261 | 0/95 | 0/93 |
| Vomiting in pregnancyPregnancy, puerperium and perinatal conditions | 1/252 | 0/261 | 0/95 | 0/93 |
| NephrolithiasisRenal and urinary disorders | 1/252 | 0/261 | 0/95 | 0/93 |
| Event | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | FE 999049 (COS Cycle 3) | GONAL-F (COS Cycle 3) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 19/252 | 27/261 | 11/95 | 13/93 |
| Biochemical pregnancyPregnancy, puerperium and perinatal conditions | 13/252 | 8/261 | 9/95 | 4/93 |
| Procedural painInjury, poisoning and procedural complications | 13/252 | 17/261 | 5/95 | 8/93 |
| Pelvic discomfortReproductive system and breast disorders | 6/252 | 13/261 | 0/95 | 6/93 |
| Pelvic painReproductive system and breast disorders | 14/252 | 11/261 | 3/95 | 5/93 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 10/252 | 9/261 | 5/95 | 4/93 |
| Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions | 13/252 | 10/261 | 3/95 | 2/93 |
| Age, Categorical(Participants) | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | Total |
|---|---|---|---|
| COS cycle 2 — <=18 years | 0 | 0 | 0 |
| COS cycle 2 — Between 18 and 65 years | 252 | 261 | 513 |
| COS cycle 2 — >=65 years | 0 | 0 | 0 |
| COS cycle 3 — <=18 years | 0 | 0 | 0 |
| COS cycle 3 — Between 18 and 65 years | 95 | 93 | 188 |
| COS cycle 3 — >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | FE 999049 (COS Cycle 2) | GONAL-F (COS Cycle 2) | Total |
|---|---|---|---|
| COS cycle 2 — Female | 252 | 261 | 513 |
| COS cycle 2 — Male | 0 | 0 | 0 |
| COS cycle 3 — Female | 95 | 93 | 188 |
| COS cycle 3 — Male | 0 | 0 | 0 |
Ran from Mar 2014 to primary completion in May 2015, 14 months.
Results were first posted in Sep 2018, 3 years 4 months after primary completion. A results delay was requested in May 2016.
Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 14 months is below that.
Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta